France Pharmacovigilance Market

ID: MRFR/MED/49693-HCR 200 Pages Nidhi Mandole Last Updated: September 17, 2026
France Pharmacovigilance Market Research Report: Size, Share, Trend Analysis By Service Type (Adverse Event Reporting, Risk Assessment, Data Mining, Pharmacovigilance Consulting), By Deployment Mode (Cloud-Based, On-Premise), By Source (Spontaneous Reporting, Literature Reports, Scheduled Reporting) and By End-user (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations) - Growth Outlook & Industry Forecast 2025 To 2035
France Pharmacovigilance Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)8.62%
2024 Market Size$ 294.5 Million
2025 Market Size$ 319.88 Million
2035 Market Size$ 731.29 Million
Key Players
Covance
IQVIA
PPD
Syneos Health
Wuxi AppTec
Medpace
Opportunities
  • Growing Public Awareness
  • Increasing Regulatory Scrutiny
  • Integration of Advanced Technologies
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Construction, BY Service Type (USD Million)
      1. 4.1.1 Adverse Event Reporting
      2. 4.1.2 Risk Assessment
      3. 4.1.3 Data Mining
      4. 4.1.4 Pharmacovigilance Consulting
    2. 4.2 Construction, BY Deployment Mode (USD Million)
      1. 4.2.1 Cloud-Based
      2. 4.2.2 On-Premise
    3. 4.3 Construction, BY Source (USD Million)
      1. 4.3.1 Spontaneous Reporting
      2. 4.3.2 Literature Reports
      3. 4.3.3 Scheduled Reporting
    4. 4.4 Construction, BY End User (USD Million)
      1. 4.4.1 Pharmaceutical Companies
      2. 4.4.2 Biotechnology Companies
      3. 4.4.3 Contract Research Organizations
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Construction
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Covance (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 IQVIA (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 PPD (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Syneos Health (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Wuxi AppTec (CN)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Medpace (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Charles River (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 PRA Health Sciences (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 FRANCE MARKET ANALYSIS BY SERVICE TYPE
    3. 6.3 FRANCE MARKET ANALYSIS BY DEPLOYMENT MODE
    4. 6.4 FRANCE MARKET ANALYSIS BY SOURCE
    5. 6.5 FRANCE MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF CONSTRUCTION
    9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
    11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
    12. 6.12 CONSTRUCTION, BY SERVICE TYPE, 2024 (% SHARE)
    13. 6.13 CONSTRUCTION, BY SERVICE TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 CONSTRUCTION, BY DEPLOYMENT MODE, 2024 (% SHARE)
    15. 6.15 CONSTRUCTION, BY DEPLOYMENT MODE, 2024 TO 2035 (USD Million)
    16. 6.16 CONSTRUCTION, BY SOURCE, 2024 (% SHARE)
    17. 6.17 CONSTRUCTION, BY SOURCE, 2024 TO 2035 (USD Million)
    18. 6.18 CONSTRUCTION, BY END USER, 2024 (% SHARE)
    19. 6.19 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY SERVICE TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DEPLOYMENT MODE, 2025-2035 (USD Million)
      3. 7.2.3 BY SOURCE, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

France Construction Market Segmentation

Construction By Service Type (USD Million, 2025-2035)

  • Adverse Event Reporting
  • Risk Assessment
  • Data Mining
  • Pharmacovigilance Consulting

Construction By Deployment Mode (USD Million, 2025-2035)

  • Cloud-Based
  • On-Premise

Construction By Source (USD Million, 2025-2035)

  • Spontaneous Reporting
  • Literature Reports
  • Scheduled Reporting

Construction By End User (USD Million, 2025-2035)

  • France Pharmacovigilance Market Companies
  • Biotechnology Companies
  • Contract Research Organizations
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.